The FusionPlex Sarcoma panel is a targeted next-generation sequencing (NGS) product to simultaneously detect and identify fusions of 26 genes associated with soft tissue cancers. FusionPlex uses RNA instead of DNA as input material, which allows for more accurate and more cost-effective fusion detection than DNA-based hybrid capture techniques. FusionPlex places gene-specific primers near known fusion breakpoints to identify RNA abnormalities with a single primer. Because FusionPlex can identify known and novel alterations, with a limited number of primers, it can detect fusions more efficiently and accurately than DNA-based approaches.